https://www.pharmaradar360.com/article/okyo-pharma-files-annual-report-and-provides-positive-corporate-update-on-financ-1de8bc1278ebcd38Pharma Surgeen2026-07-20T11:13:00.000ZOKYO Pharma Files Annual Report and Provides Positive Corporate Update on Financial Strength and Phase 3 Urcosimod Trialhttps://www.pharmaradar360.com/article/armata-submits-phase-3-protocol-for-antibiotic-resistant-drug-46c6d0076f055e28Pharma Surgeen2026-07-20T11:10:51.000ZArmata submits Phase 3 protocol for antibiotic-resistant drughttps://www.pharmaradar360.com/article/veraxa-biotech-announces-regulatory-progress-with-its-bitac-tce-development-plan-cdf089c02ae6022cPharma Surgeen2026-07-20T11:09:28.000ZVERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Planhttps://www.pharmaradar360.com/article/inmune-bio-completes-commercial-manufacturing-milestone-supporting-planned-globa-d200603f476f8bd3Pharma Surgeen2026-07-20T11:09:07.000ZINmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platformhttps://www.pharmaradar360.com/article/pune-fda-s-ai-complaint-portal-receives-293-food-and-drug-complaints-in-four-day-5a2363ea9552ff0cPharma Surgeen2026-07-20T11:08:31.000ZPune: FDA’s AI Complaint Portal Receives 293 Food And Drug Complaints In Four Dayshttps://www.pharmaradar360.com/article/can-ai-fix-pharma-s-last-mile-delivery-blind-spot-fdb0bde08f11c060Pharma Surgeen2026-07-20T11:08:02.000ZCan AI Fix Pharma's Last-Mile Delivery Blind Spot?https://www.pharmaradar360.com/article/can-fite-biopharma-nyse-canf-to-present-phase-2a-pancreatic-cancer-data-67ba09d6ce162c17Pharma Surgeen2026-07-20T11:04:55.000ZCan-Fite BioPharma (NYSE: CANF) to present Phase 2a pancreatic cancer datahttps://www.pharmaradar360.com/article/medtronic-to-announce-financial-results-for-its-first-quarter-of-fiscal-year-202-cdf53bbd085cc097Pharma Surgeen2026-07-20T11:00:00.000ZMedtronic to announce financial results for its first quarter of fiscal year 2027https://www.pharmaradar360.com/article/pancreatic-cancer-patient-alive-18-months-after-second-line-namodenoson-c89743fdac0a1154Pharma Surgeen2026-07-20T11:00:00.000ZPancreatic cancer patient alive 18+ months after second-line Namodenosonhttps://www.pharmaradar360.com/article/inmune-bio-s-cord-tissue-process-supports-planned-phase-3-trial-4e392a24ea47c05bPharma Surgeen2026-07-20T11:00:00.000ZINmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trialhttps://www.pharmaradar360.com/article/compugen-s-cancer-immunotherapy-update-is-set-for-aug-3-042905cbb332ebb2Pharma Surgeen2026-07-20T11:00:00.000ZCompugen's Cancer Immunotherapy Update Is Set for Aug. 3https://www.pharmaradar360.com/article/veraxa-cancer-candidate-targets-two-markers-while-sparing-others-a7a8c86874aa56ccPharma Surgeen2026-07-20T11:00:00.000ZVERAXA cancer candidate targets two markers while sparing othershttps://www.pharmaradar360.com/article/clinigen-appoints-greg-skalicky-as-chief-executive-officer-3c706b48f07d073cPharma Surgeen2026-07-20T11:00:00.000ZClinigen Appoints Greg Skalicky as Chief Executive Officerhttps://www.pharmaradar360.com/article/armata-pharmaceuticals-achieves-key-progress-across-clinical-regulatory-and-manu-95ee25e484007f09Pharma Surgeen2026-07-20T11:00:00.000ZArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02https://www.pharmaradar360.com/article/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-de34734338def5c4Pharma Surgeen2026-07-20T10:59:00.000ZBristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIAhttps://www.pharmaradar360.com/article/betting-on-biotech-clinical-trials-enter-prediction-markets-ae98a736a8f729adPharma Surgeen2026-07-20T10:55:54.000ZBetting on biotech: Clinical trials enter prediction marketshttps://www.pharmaradar360.com/article/mission-therapeutics-divests-acute-kidney-injury-drug-mtx652-in-292m-dimerix-dea-dfd2eada78fbcfa1Pharma Surgeen2026-07-20T10:54:19.000ZMission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix dealhttps://www.pharmaradar360.com/article/ukhsa-s-chief-scientist-reminds-families-how-to-beat-the-heat-as-schools-break-f-caf7d7411e944bb3Pharma Surgeen2026-07-20T10:53:50.000ZUKHSA's Chief Scientist reminds families how to Beat the Heat as schools break for summerhttps://www.pharmaradar360.com/article/wcm-investment-management-llc-purchases-26-813-522-shares-of-teva-pharmaceutical-2b9ccadaf2ab22a6Pharma Surgeen2026-07-20T10:27:12.000ZWCM Investment Management LLC Purchases 26,813,522 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/uk-biotech-financing-continues-recovery-trajectory-on-five-year-q2-high-101aabbb24a3bb8ePharma Surgeen2026-07-20T10:25:33.000ZUK biotech financing continues recovery trajectory on five-year Q2 highhttps://www.pharmaradar360.com/article/4dmt-reports-positive-2-year-prism-phase-2b-data-for-4d-150-db50f42d5b3adec3Pharma Surgeen2026-07-20T10:22:21.000Z4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150https://www.pharmaradar360.com/article/xencor-shares-kidney-cancer-trial-results-at-esmo-20041aa2b4ee9769Pharma Surgeen2026-07-20T10:21:52.000ZXencor Shares Kidney Cancer Trial Results at ESMOhttps://www.pharmaradar360.com/article/inflammasome-reports-positive-phase-2-k8-results-d643447a8a619d69Pharma Surgeen2026-07-20T10:21:15.000ZInflammasome Reports Positive Phase 2 K8 Resultshttps://www.pharmaradar360.com/article/eli-lilly-bets-3-8-billion-on-ataibeckley-psychedelics-ea33bc341702ab4bPharma Surgeen2026-07-20T10:18:54.000ZEli Lilly Bets $3.8 Billion on AtaiBeckley Psychedelicshttps://www.pharmaradar360.com/article/nuvation-ceo-david-hung-details-leadership-strategies-and-career-motivations-in-395028fc7e6ecb63Pharma Surgeen2026-07-20T10:17:54.000ZNuvation CEO David Hung Details Leadership Strategies and Career Motivations in Biotechhttps://www.pharmaradar360.com/article/the-patient-information-leaflet-is-it-really-working-for-patients-a4bc9d2d423e5951Pharma Surgeen2026-07-20T10:13:57.000ZThe patient information leaflet: is it really working for patients?https://www.pharmaradar360.com/article/biotech-breakthroughs-in-treating-uterine-disorders-e65e91bf9c6dd4fePharma Surgeen2026-07-20T10:13:21.000ZBiotech Breakthroughs in Treating Uterine Disordershttps://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-20T10:09:57.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/2025-7-66-4316-2014-270-b978e6a115602a41Pharma Surgeen2026-07-20T10:07:43.000ZΠαροχές εταιρειών προϊόντων αρμοδιότητας ΕΟΦ έτους 2025 δυνάμει της παραγράφου 7 του άρθρου 66 του Ν. 4316/2014 (Α΄ 270)https://www.pharmaradar360.com/article/recce-pharmaceuticals-asx-rce-share-purchase-plan-deadline-extended-what-investo-63de4de46a7de840Pharma Surgeen2026-07-20T10:06:00.000ZRecce Pharmaceuticals (ASX:RCE): Share Purchase Plan Deadline Extended---What Investors Need to Knowhttps://www.pharmaradar360.com/article/dwwd-etf-profile-dividends-returns-han-dwwd-3aff3ac07d8ed8daPharma Surgeen2026-07-20T10:04:20.000ZDWWD ETF Profile: Dividends, Returns (HAN:DWWD)https://www.pharmaradar360.com/article/how-exposed-is-the-u-s-pharmaceutical-supply-chain-to-china-s-updated-export-con-09130df36f23b4ffPharma Surgeen2026-07-20T10:03:11.000ZHow Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?https://www.pharmaradar360.com/article/axios-c-suite-pfizer-ceo-on-biotech-s-china-warning-506de2d800745dacPharma Surgeen2026-07-20T10:00:46.000ZAxios C-Suite: Pfizer CEO on biotech's China warninghttps://www.pharmaradar360.com/article/lecanemab-for-ad-shows-sustained-benefit-in-real-world-study-11713568d7bcb3d5Pharma Surgeen2026-07-20T09:48:42.000ZLecanemab for AD Shows Sustained Benefit in Real-World Studyhttps://www.pharmaradar360.com/article/fda-crackdown-tukaram-mundhe-reveals-maharashtra-s-biggest-food-complaint-hotspo-060b25c7d3e8594bPharma Surgeen2026-07-20T09:44:16.000ZFDA Crackdown: Tukaram Mundhe Reveals Maharashtra's Biggest Food Complaint Hotspothttps://www.pharmaradar360.com/article/blossomhill-joins-biotech-ipo-stampede-with-small-molecule-bet-b5b7eaba46ea7cf6Pharma Surgeen2026-07-20T09:39:47.000ZBlossomHill joins biotech IPO stampede with small molecule bethttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-16-august-2026-e87634fb03727675Pharma Surgeen2026-07-20T09:36:46.000ZWeekly all-cause mortality surveillance: week ending 16 August 2026https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-19-july-2026-6ea0cfec207911edPharma Surgeen2026-07-20T09:36:30.000ZWeekly all-cause mortality surveillance: week ending 19 July 2026https://www.pharmaradar360.com/article/a-look-cleanroom-technology-events-2026-2027-75b305a67eecfe2cPharma Surgeen2026-07-20T09:21:04.000ZA look: Cleanroom technology events 2026-2027https://www.pharmaradar360.com/article/india-approves-first-dengue-vaccine-qdenga-for-people-aged-4-60-years-b8a64a7bc4f48314Pharma Surgeen2026-07-20T09:08:52.000ZIndia approves first dengue vaccine QDENGA for people aged 4-60 yearshttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-information-for-healthcare-p-a9d27fb6d5e14baePharma Surgeen2026-07-20T09:03:25.000ZMeningococcal B (MenB) time limited vaccination offer: information for healthcare practitionershttps://www.pharmaradar360.com/article/latigo-bets-its-ipo-on-non-opioid-pain-data-51c683fdd7bb0c07Pharma Surgeen2026-07-20T09:00:00.000ZLatigo bets its IPO on non-opioid pain datahttps://www.pharmaradar360.com/article/uk-biotech-venture-investment-reaches-five-year-high-in-q2-2026-fc067bfa69405ae4Pharma Surgeen2026-07-20T09:00:00.000ZUK biotech venture investment reaches five-year high in Q2 2026https://www.pharmaradar360.com/article/galderma-rolls-out-alastin-regenerative-skincare-across-jpac-region-c32c8d792f240212Pharma Surgeen2026-07-20T08:59:22.000ZGalderma rolls out Alastin regenerative skincare across JPAC regionhttps://www.pharmaradar360.com/article/uk-biotech-venture-investment-remains-buoyant-in-q2-ab08ab2a9e53eb08Pharma Surgeen2026-07-20T08:58:52.000ZUK biotech venture investment remains buoyant in Q2https://www.pharmaradar360.com/article/dyslipidemia-which-is-familiar-with-hyperlipidemia-is-considered-a-national-chro-169046cd4b486de6Pharma Surgeen2026-07-20T08:46:13.000ZDyslipidemia, which is familiar with hyperlipidemia, is considered a "national chronic disease" alon..https://www.pharmaradar360.com/article/large-ems-response-at-grifols-pharmaceutical-plant-in-clayton-ae24d2f34adfae05Pharma Surgeen2026-07-20T08:45:30.000ZLarge EMS response at Grifols pharmaceutical plant in Claytonhttps://www.pharmaradar360.com/article/tukaram-mundhe-maharashtra-fda-s-food-safety-enforcement-drive-bc16db20c832cf82Pharma Surgeen2026-07-20T08:41:58.000ZTukaram Mundhe: Maharashtra FDA's Food Safety Enforcement Drivehttps://www.pharmaradar360.com/article/ubfc-etf-profile-dividends-returns-swb-ubfc-2fcfd46b21ec4f71Pharma Surgeen2026-07-20T08:39:12.000ZUBFC ETF Profile: Dividends, Returns (SWB:UBFC)https://www.pharmaradar360.com/article/kolon-tissuegene-s-tg-c-fails-to-meet-statistical-significance-in-u-s-phase-3-8454a49c2174a7a8Pharma Surgeen2026-07-20T08:35:32.000ZKolon TissueGene's TG-C Fails to Meet Statistical Significance in U.S. Phase 3https://www.pharmaradar360.com/article/flu-vaccines-for-children-and-young-people-for-2026-to-2027-750e454b72aae8f2Pharma Surgeen2026-07-20T08:30:07.000ZFlu vaccines for children and young people for 2026 to 2027https://www.pharmaradar360.com/article/flu-vaccination-letter-template-for-at-risk-patients-and-carers-f8d0a2827f858979Pharma Surgeen2026-07-20T08:30:07.000ZFlu vaccination: letter template for at risk patients and carershttps://www.pharmaradar360.com/article/25-transfers-in-two-decades-meet-ias-officer-tukaram-mundhe-leading-maharashtra-53cf7bce17f0791dPharma Surgeen2026-07-20T08:13:03.000Z25 Transfers in Two Decades: Meet IAS Officer Tukaram Mundhe, Leading Maharashtra’s Food Safety Crackdownhttps://www.pharmaradar360.com/article/lundbeck-takes-important-step-in-global-phase-3-trial-with-epilepsy-treatment-ca-c904c4cac934ad66Pharma Surgeen2026-07-20T08:12:01.000ZLundbeck takes important step in global phase 3 trial with epilepsy treatment candidatehttps://www.pharmaradar360.com/article/register-medical-devices-to-place-on-the-market-3019846827ce19e8Pharma Surgeen2026-07-20T08:06:20.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/guidance-medical-devices-legal-requirements-for-specific-medical-products-a3bc1151bebfa6a3Pharma Surgeen2026-07-20T08:06:17.000ZGuidance: Medical devices: legal requirements for specific medical productshttps://www.pharmaradar360.com/article/guidance-custom-made-medical-devices-in-great-britain-08caf003423fd6bcPharma Surgeen2026-07-20T08:06:13.000ZGuidance: Custom-made medical devices in Great Britainhttps://www.pharmaradar360.com/article/kolon-tissuegene-misses-efficacy-in-us-phase-3-pursues-fda-talks-chosunbiz-beaa3bd1f4f51130Pharma Surgeen2026-07-20T08:02:00.000ZKolon TissueGene misses efficacy in US phase 3, pursues FDA talks - CHOSUNBIZhttps://www.pharmaradar360.com/article/a-rising-tide-scenario-why-other-big-pharmas-could-follow-lilly-into-psychedelic-d34c3d099447c9faPharma Surgeen2026-07-20T08:00:00.000Z‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicshttps://www.pharmaradar360.com/article/dekaz-e1d1cbcc98a4434aPharma Surgeen2026-07-20T07:58:26.000ZΑνάκληση της Άδειας Χονδρικής πώλησης φαρμάκων για Ανθρώπινη Χρήση στο πρατήριο της εταιρείας DEKAZ ΑΕhttps://www.pharmaradar360.com/article/regulatory-round-up-20-july-2026-2361df46dde1adc9Pharma Surgeen2026-07-20T07:49:14.000ZRegulatory round-up: 20 July 2026https://www.pharmaradar360.com/article/202412-aloha-nails-cosmetics-repair-gel-milky-lilac-tpo-2fc9b872145d525bPharma Surgeen2026-07-20T07:47:54.000ZΑνάκληση της παρτίδας 202412 του Καλλυντικού προϊόντος ALOHA Nails & Cosmetics REPAIR GEL MILKY LILAC, λόγω παρουσίας TPOhttps://www.pharmaradar360.com/article/world-usp-grade-magnesium-hydroxide-market-analysis-forecast-size-trends-and-ins-44765223f03285f7Pharma Surgeen2026-07-20T07:46:12.000ZWorld Usp Grade Magnesium Hydroxide - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/272955-ivd-general-kits-sta-c-k-prest-bb425a5b49d75aafPharma Surgeen2026-07-20T07:39:33.000ZΑνάκληση της παρτίδας 272955 του Ιατροτεχνολογικού προϊόντος κατηγορίας IVD General, Kits STA- C.K. Prest.https://www.pharmaradar360.com/article/maharashtra-fda-plans-us-style-digital-food-safety-system-blockchain-tracking-as-fa613b86e31c7cc1Pharma Surgeen2026-07-20T07:20:07.000ZMaharashtra FDA Plans US-Style Digital Food Safety System, Blockchain Tracking as Complaints Surgehttps://www.pharmaradar360.com/article/92890-cotton-absorbent-gauze-ref-6-1003-2-ref-6-1006-2-0169395d712d78acPharma Surgeen2026-07-20T07:19:11.000ZΑπόφαση απαγόρευσης διακίνησης και διάθεσης – 92890 Cotton absorbent gauze (REF: 6-1003Ν2 & REF: 6-1006Ν2)https://www.pharmaradar360.com/article/koreabio-seeks-closer-biotech-ties-with-taiwan-15e7326c3b8774a5Pharma Surgeen2026-07-20T07:18:34.000ZKoreaBIO seeks closer biotech ties with Taiwanhttps://www.pharmaradar360.com/article/dimerix-secures-funding-to-advance-dmx-200-phase-3-trial-1a909bb32060c292Pharma Surgeen2026-07-20T07:17:18.000ZDimerix Secures Funding to Advance DMX-200 Phase 3 Trialhttps://www.pharmaradar360.com/article/la-aemps-informa-de-la-entrada-en-aplicacion-del-reglamento-de-ejecucion-ue-2024-c41f098acdc22273Pharma Surgeen2026-07-20T07:16:46.000ZLa AEMPS informa de la entrada en aplicación del Reglamento de Ejecución (UE) 2024/1973 sobre el uso de determinados antimicrobianos en animaleshttps://www.pharmaradar360.com/article/trellis-raises-9m-to-advance-calpurbatug-phase-2-trial-a17a3d5a32117acdPharma Surgeen2026-07-20T07:10:09.000ZTrellis Raises $9M to Advance Calpurbatug Phase 2 Trialhttps://www.pharmaradar360.com/article/coregen-wins-fda-ind-clearance-for-crg-150-c392a1bf28f33ccaPharma Surgeen2026-07-20T07:08:26.000ZCoRegen Wins FDA IND Clearance for CRG-150https://www.pharmaradar360.com/article/what-could-drive-private-capital-participation-in-india-s-biotech-sector-97a8ec88b7ff9f32Pharma Surgeen2026-07-20T07:08:22.000ZWhat could drive private capital participation in India's biotech sector?https://www.pharmaradar360.com/article/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose-8457a82aa7f80a99Pharma Surgeen2026-07-20T07:00:48.000ZEuropean Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year oldshttps://www.pharmaradar360.com/article/when-the-phase-3-dies-after-the-acquisition-the-site-level-fallout-no-one-plans-e2af19f34c1b5bbcPharma Surgeen2026-07-20T07:00:21.000ZWhen the Phase 3 Dies After the Acquisition: The Site-Level Fallout No One Plans Forhttps://www.pharmaradar360.com/article/biovica-receives-first-work-order-under-expanded-master-services-agreement-with-02cfbb4859d1d7a5Pharma Surgeen2026-07-20T07:00:00.000ZBiovica receives first work order under expanded Master Services Agreement with leading global pharmaceutical customerhttps://www.pharmaradar360.com/article/fda-s-ai-complaint-portal-gets-267-complaints-in-pune-division-in-4-days-e6789a91627f8a57Pharma Surgeen2026-07-20T06:59:49.000ZFDA’s AI Complaint Portal Gets 267 Complaints in Pune Division in 4 Dayshttps://www.pharmaradar360.com/article/stepping-up-in-innsbruck-3616a1ea7e13f465Pharma Surgeen2026-07-20T06:54:22.000ZStepping up in Innsbruckhttps://www.pharmaradar360.com/article/samsung-biologics-to-buy-polypeptide-for-1-9-bn-in-korea-s-biggest-pharma-deal-2f55980827888015Pharma Surgeen2026-07-20T06:54:03.000ZSamsung Biologics to buy PolyPeptide for $1.9 bn in Korea’s biggest pharma dealhttps://www.pharmaradar360.com/article/cytosurge-elects-veteran-biotech-executive-investor-and-company-builder-luba-gre-eef61bc565bef83ePharma Surgeen2026-07-20T06:45:26.000ZCytosurge elects veteran biotech executive, investor, and company builder Luba Greenwood, J.D., to its Board of Directorshttps://www.pharmaradar360.com/article/fda-raids-two-pmc-hospitals-over-unsafe-drug-dispensing-suspends-10-licences-of-fef7bf0b33eb8269Pharma Surgeen2026-07-20T06:15:17.000ZFDA raids two PMC hospitals over unsafe drug dispensing; suspends 10 licences of eateries, bakeries and dairieshttps://www.pharmaradar360.com/article/big-pharma-s-next-billion-dollar-bet-is-magic-mushrooms-mdma-and-lsd-could-psych-79dd7b298a45a141Pharma Surgeen2026-07-20T06:09:49.000ZBig Pharma's Next Billion-Dollar Bet Is Magic Mushrooms, MDMA And LSD. Could Psychedelic Drugs Change Mental Healthcare Forever?https://www.pharmaradar360.com/article/japanese-drugmaker-takeda-s-qdenga-becomes-first-dengue-vaccine-approved-in-indi-ac24f784c64ba846Pharma Surgeen2026-07-20T06:01:00.000ZJapanese drugmaker Takeda's QDENGA becomes first dengue vaccine approved in Indiahttps://www.pharmaradar360.com/article/takeda-pharmaceutical-s-qdenga-tak-003-becomes-first-dengue-vaccine-to-be-approv-fa4b1e941a201333Pharma Surgeen2026-07-20T05:45:00.000ZTakeda Pharmaceutical's Qdenga (Tak-003) Becomes First Dengue Vaccine To Be Approved In India- Statementhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-tian-an-pharmaceutical-co-ltd-otc-tnph-9334f966b46da200Pharma Surgeen2026-07-20T05:32:26.000ZEnterprise value to EBIT forward of Tian'an Pharmaceutical Co., Ltd. – OTC:TNPHhttps://www.pharmaradar360.com/article/hlb-therapeutics-completes-global-phase-3-patient-enrollment-for-rgn-259-3bb025d0a14ed96aPharma Surgeen2026-07-20T05:29:42.000ZHLB Therapeutics Completes Global Phase 3 Patient Enrollment for RGN-259https://www.pharmaradar360.com/article/trump-purge-at-fda-and-usda-triggers-food-safety-brain-drain-211ed6056a9146daPharma Surgeen2026-07-20T05:27:05.000ZTrump purge at FDA and USDA triggers food safety ‘brain drain’https://www.pharmaradar360.com/article/hlb-fails-in-third-fda-bid-can-it-rebuild-shattered-market-trust-215dfb485d8834d1Pharma Surgeen2026-07-20T05:23:39.000ZHLB Fails in Third FDA Bid—Can It Rebuild Shattered Market Trust?https://www.pharmaradar360.com/article/atai-stock-slips-after-blockbuster-week-cathie-wood-calls-3-8b-lilly-deal-well-d-faedea519d8f38e6Pharma Surgeen2026-07-20T05:18:00.000ZATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholdershttps://www.pharmaradar360.com/article/fostering-new-opportunities-in-the-greater-bay-area-and-asia-s-pharmaceutical-in-f4f3d36ffb101e82Pharma Surgeen2026-07-20T04:52:00.000ZFostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industryhttps://www.pharmaradar360.com/article/vietnam-pharma-stocks-gain-attention-as-drug-market-nears-10-billion-a6c0dcb8cc18836fPharma Surgeen2026-07-20T04:29:02.000ZVietnam pharma stocks gain attention as drug market nears $10 billionhttps://www.pharmaradar360.com/article/hong-kong-stocks-in-focus-innovation-driven-pharmaceutical-stocks-rebound-across-1ce48bbe2e7c29e3Pharma Surgeen2026-07-20T04:24:09.000ZHong Kong Stocks in Focus | Innovation‑driven pharmaceutical stocks rebound across the board; 38 innovative drugs received approval for market launch in the first half of the year, with domestically developed products accounting for over 80% of the total.https://www.pharmaradar360.com/article/suven-life-plans-neuroscience-breakthrough-by-2026-27-and-singapore-expansion-3c82c76fd9efd7edPharma Surgeen2026-07-20T04:17:31.000ZSuven Life Plans Neuroscience Breakthrough by 2026-27 and Singapore Expansionhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-aurisco-pharmaceutical-co-ltd-class-a-sse-605116-f67668eac3e5f412Pharma Surgeen2026-07-20T04:15:32.000ZPrice to earnings forward of Aurisco Pharmaceutical Co. Ltd. Class A – SSE:605116https://www.pharmaradar360.com/article/a-pancreatic-cancer-vaccine-shows-promise-in-a-phase-1-clinical-trial-400f6507bfa41d71Pharma Surgeen2026-07-20T04:05:24.000ZA Pancreatic Cancer Vaccine Shows Promise in a Phase 1 Clinical Trialhttps://www.pharmaradar360.com/article/maha-fda-launches-country-s-first-ai-powered-grievance-portal-to-strengthen-drug-0d57e97bae531cdbPharma Surgeen2026-07-20T03:54:34.000ZMaha FDA launches country's first AI-powered grievance portal to strengthen drug safetyhttps://www.pharmaradar360.com/article/fda-clears-taylor-farms-lettuce-of-cyclospora-contamination-00395b2f818c5b06Pharma Surgeen2026-07-20T03:14:52.000ZFDA Clears Taylor Farms Lettuce of Cyclospora Contaminationhttps://www.pharmaradar360.com/article/is-collegium-pharmaceutical-coll-still-undervalued-as-its-growth-narrative-holds-ed5be6e290a36264Pharma Surgeen2026-07-20T03:14:00.000ZIs Collegium Pharmaceutical (COLL) Still Undervalued As Its Growth Narrative Holds Up?https://www.pharmaradar360.com/article/stay-bullish-despite-the-rough-week-aerospace-finance-biotech-and-ai-ndx-d83081917c32cccePharma Surgeen2026-07-20T02:51:51.000ZStay Bullish Despite The Rough Week: Aerospace, Finance, Biotech, And AI (NDX)https://www.pharmaradar360.com/article/inflammasome-therapeutics-reports-positive-six-month-phase-2-results-for-k8-in-g-31cb61a1131de749Pharma Surgeen2026-07-20T02:46:59.000ZInflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophyhttps://www.pharmaradar360.com/article/world-tablet-capsule-counting-machine-market-analysis-forecast-size-trends-and-i-7d8d204a143b522aPharma Surgeen2026-07-20T02:41:13.000ZWorld Tablet Capsule Counting Machine - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/samsung-biologics-to-launch-1-8-billion-all-cash-bid-for-polypeptide-7baf5c76aeb1e643Pharma Surgeen2026-07-20T01:53:58.000ZSamsung Biologics to launch $1.8 billion all-cash bid for PolyPeptidehttps://www.pharmaradar360.com/article/cyclospora-outbreak-update-fda-clears-taylor-farms-lettuce-bd9d6d6d2b39ec11Pharma Surgeen2026-07-20T01:30:16.000ZCyclospora Outbreak Update: FDA Clears Taylor Farms Lettucehttps://www.pharmaradar360.com/article/korean-pharmaceutical-and-bio-association-launches-gmp-regulation-consultation-h-185445544db2baa7Pharma Surgeen2026-07-20T01:16:00.000ZKorean Pharmaceutical and Bio Association Launches GMP Regulation Consultation Hotlinehttps://www.pharmaradar360.com/article/fda-clears-taylor-farms-in-cyclospora-investigation-35143150d9010bfaPharma Surgeen2026-07-20T00:47:34.000ZFDA Clears Taylor Farms in Cyclospora Investigationhttps://www.pharmaradar360.com/article/osteonic-receives-approval-for-suturepasser-sports-medicine-surgical-tool-accele-0b8fbdc5b6ef664bPharma Surgeen2026-07-20T00:46:17.000ZOsteonic Receives Approval for 'Suturepasser' Sports Medicine Surgical Tool... Accelerates Supply Through Zimmer Biomethttps://www.pharmaradar360.com/article/suven-life-raises-858-cr-for-cns-drug-trials-f34660c423c006fcPharma Surgeen2026-07-20T00:39:53.000ZSuven Life Raises ₹858 Cr for CNS Drug Trialshttps://www.pharmaradar360.com/article/building-a-workforce-engine-for-biomanufacturing-4c6d9e6d8c5d2d93Pharma Surgeen2026-07-20T00:05:33.000ZBuilding a workforce engine for biomanufacturinghttps://www.pharmaradar360.com/article/why-early-de-risking-is-redefining-the-path-to-ind-71ad90a82baa0b7cPharma Surgeen2026-07-20T00:05:33.000ZWhy early de-risking is redefining the path to INDhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-ea4dee9e111b6055Pharma Surgeen2026-07-20T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-73eaec1a2cbd3447Pharma Surgeen2026-07-20T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-1d9a630ce2282e1bPharma Surgeen2026-07-20T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-1f59a12563237366Pharma Surgeen2026-07-20T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-15187d1c341b2c36Pharma Surgeen2026-07-20T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-7b694a87ce4d7353Pharma Surgeen2026-07-20T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-8500f81d6969481bPharma Surgeen2026-07-20T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-40dd926ed1ee3127Pharma Surgeen2026-07-20T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-6b317818e1f5533bPharma Surgeen2026-07-20T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-f69f6cdae0257209Pharma Surgeen2026-07-20T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-6ef7939200ecd808Pharma Surgeen2026-07-20T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-fafa4be92a12a69aPharma Surgeen2026-07-20T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-3a7a96a8b08ce710Pharma Surgeen2026-07-20T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-9d5e7b42638e9db6Pharma Surgeen2026-07-20T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/office-of-the-secretary-amended-notice-of-meeting-8912e2d9dccaf71fPharma Surgeen2026-07-20T00:00:00.000ZOffice of the Secretary; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-3b6ec579669d6b19Pharma Surgeen2026-07-20T00:00:00.000ZPrivacy Act of 1974; System of Recordshttps://www.pharmaradar360.com/article/medicare-program-inflation-reduction-act-of-2022-ira-medicare-drug-price-negotia-c4602e089ac69771Pharma Surgeen2026-07-20T00:00:00.000ZMedicare Program; Inflation Reduction Act of 2022 (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Requesthttps://www.pharmaradar360.com/article/food-standards-of-identity-modernization-pasteurized-orange-juice-880832ff9b7e6f11Pharma Surgeen2026-07-20T00:00:00.000ZFood Standards of Identity Modernization; Pasteurized Orange Juicehttps://www.pharmaradar360.com/article/agency-information-collection-request-30-day-public-comment-request-3161abfadc707cedPharma Surgeen2026-07-20T00:00:00.000ZAgency Information Collection Request; 30-Day Public Comment Requesthttps://www.pharmaradar360.com/article/evaluation-of-fructose-zinc-citric-acid-and-sperm-quality-in-infertile-male-subj-cf4fb4f0d20f9e9bPharma Surgeen2026-07-20T00:00:00.000ZEvaluation of Fructose, Zinc, Citric Acid, and Sperm Quality in Infertile Male Subjects Attending Fertility Clinic in Lagos Metropolishttps://www.pharmaradar360.com/article/gender-based-experiences-of-people-living-with-hiv-in-owerri-north-local-governm-47188f034f184747Pharma Surgeen2026-07-20T00:00:00.000ZGender-based Experiences of People Living with HIV in Owerri North Local Government Area of Imo State, Nigeriahttps://www.pharmaradar360.com/article/normative-data-and-repeatability-of-a-4-khz-pure-tone-psychoacoustic-tuning-curv-f925428c472b1fa6Pharma Surgeen2026-07-20T00:00:00.000ZNormative Data and Repeatability of a 4-kHz Pure-Tone Psychoacoustic Tuning Curve Using a Single Clinical Audiometerhttps://www.pharmaradar360.com/article/nanobots-in-lung-cancer-therapy-an-overview-36da52e84dd34725Pharma Surgeen2026-07-20T00:00:00.000ZNanobots in Lung Cancer Therapy: An Overviewhttps://www.pharmaradar360.com/article/a-closed-loop-age-friendly-medical-platform-from-ai-consultation-to-post-diagnos-c5ef98cdb2096ac1Pharma Surgeen2026-07-20T00:00:00.000ZA CLOSED-LOOP AGE-FRIENDLY MEDICAL PLATFORM: FROM AI CONSULTATION TO POST-DIAGNOSIS CAREhttps://www.pharmaradar360.com/article/interactions-between-hyperglycaemia-drug-metabolism-and-toxicity-profiles-a-syst-fd7b595bf674bef1Pharma Surgeen2026-07-20T00:00:00.000ZInteractions Between Hyperglycaemia, Drug Metabolism, and Toxicity Profiles: A Systems Biology Reviewhttps://www.pharmaradar360.com/article/meta-analysis-of-the-arterial-variations-of-the-suprarenal-arteries-and-their-cl-6daf84f241efedb6Pharma Surgeen2026-07-20T00:00:00.000ZMeta-Analysis of the Arterial Variations of the Suprarenal Arteries and Their Clinical Significancehttps://www.pharmaradar360.com/article/delineating-the-intradural-space-a-comparative-series-of-spinal-cord-lesions-4d0465044f4b72fcPharma Surgeen2026-07-20T00:00:00.000ZDelineating the Intradural Space: A Comparative Series of Spinal Cord Lesionshttps://www.pharmaradar360.com/article/nurses-experiences-implementing-clinical-practice-guidelines-for-detecting-and-m-713e6360e0c32c4dPharma Surgeen2026-07-20T00:00:00.000ZNurses’ experiences implementing clinical practice guidelines for detecting and managing chronic kidney disease in Eswatini’s primary healthcare facilities: A qualitative studyhttps://www.pharmaradar360.com/article/phenotypic-detection-and-associated-factors-of-ampc-beta-lactamase-among-clinica-50fa90f3277a0cd8Pharma Surgeen2026-07-20T00:00:00.000ZPhenotypic detection and associated factors of AmpC beta-lactamase among clinical isolates of &lt;i&gt;Escherichia coli&lt;/i&gt;, &lt;i&gt;Klebsiella species&lt;/i&gt;, and &lt;i&gt;Proteus species&lt;/i&gt; at the National Hospital of Sri Lankahttps://www.pharmaradar360.com/article/admission-endothelial-activation-and-stress-index-and-echocardiographic-rv-pa-co-2fbeb3b6c5eda27aPharma Surgeen2026-07-20T00:00:00.000ZAdmission Endothelial Activation and Stress Index and Echocardiographic RV-PA Coupling for Early Risk Stratification in Intermediate-Risk Acute Pulmonary Embolismhttps://www.pharmaradar360.com/article/safe-implementation-of-robotic-colorectal-surgery-balancing-surgical-training-an-a4c2a2190bddac1dPharma Surgeen2026-07-20T00:00:00.000ZSafe Implementation of Robotic Colorectal Surgery: Balancing Surgical Training and Patient Safety with the Dual-Console Systemhttps://www.pharmaradar360.com/article/patient-reported-health-status-and-clinical-outcomes-after-cto-pci-versus-optima-c82cba1acac8a1ccPharma Surgeen2026-07-20T00:00:00.000ZPatient-Reported Health Status and Clinical Outcomes After CTO-PCI Versus Optimal Medical Therapy: A 12-Month Retrospective Observational Cohort Analysishttps://www.pharmaradar360.com/article/an-equity-embedded-protocol-agnostic-pre-trial-navigation-model-for-canadian-blo-a702face4fad5433Pharma Surgeen2026-07-20T00:00:00.000ZAn Equity-Embedded, Protocol-Agnostic Pre-Trial Navigation Model for Canadian Blood Cancer Trials: Findings from the Myeloma Canada Phase 0 Workshophttps://www.pharmaradar360.com/article/sars-cov-2-wastewater-surveillance-in-a-central-chinese-metropolis-variant-respo-f66899a9396ac66dPharma Surgeen2026-07-20T00:00:00.000ZSARS-CoV-2 wastewater surveillance in a central Chinese metropolis: variant responses and correlation with clinical caseshttps://www.pharmaradar360.com/article/comparison-of-intraoperative-hemodynamic-parameters-between-propofol-and-remimaz-125f116cc3423af1Pharma Surgeen2026-07-20T00:00:00.000ZComparison of intraoperative hemodynamic parameters between propofol- and remimazolam-based total intravenous anesthesia in patients undergoing robotic gynecologic surgery: a randomized controlled trial protocolhttps://www.pharmaradar360.com/article/radiomics-and-clinical-data-predict-pseudoprogression-after-radiotherapy-in-high-3104fb64e4d15ae0Pharma Surgeen2026-07-20T00:00:00.000ZRadiomics and clinical data predict pseudoprogression after radiotherapy in high-grade gliomahttps://www.pharmaradar360.com/article/clinical-imaging-fusion-model-for-risk-assessment-of-clinically-significant-pros-f45ed9722b9521dcPharma Surgeen2026-07-20T00:00:00.000ZClinical-imaging fusion model for risk assessment of clinically significant prostate cancerhttps://www.pharmaradar360.com/article/low-energy-availability-the-gut-microbiome-and-bone-health-in-athletes-a-mechani-3ef1f487c33a3f9ePharma Surgeen2026-07-20T00:00:00.000ZLow energy availability, the gut microbiome, and bone health in athletes: a mechanistic narrative review based on athlete evidence and clinical analogueshttps://www.pharmaradar360.com/article/changing-trends-in-antibiotic-susceptibility-pattern-among-clinical-isolates-of-ac74a164769f98b0Pharma Surgeen2026-07-20T00:00:00.000ZChanging Trends in Antibiotic Susceptibility Pattern Among Clinical Isolates of &lt;i&gt;Pseudomonas&lt;/i&gt; Species in a Tertiary Care Hospital in Nepalhttps://www.pharmaradar360.com/article/clinical-reflection-and-reasoning-competencies-among-nursing-students-in-health-75734b6b7ceefb2bPharma Surgeen2026-07-20T00:00:00.000ZClinical Reflection and Reasoning Competencies among Nursing Students in Health Science Universities: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/transcriptome-wide-identification-of-hub-genes-and-therapeutic-targets-in-type-2-9c0b13d71b628c6bPharma Surgeen2026-07-20T00:00:00.000ZTranscriptome-Wide Identification of Hub Genes and Therapeutic Targets in Type 2 Diabetes Mellitus Through Integrated Bioinformatics and Molecular Docking-Based Drug Repurposinghttps://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-adult-patients-presenting-to-the-emerge-1c3074fb16e39293Pharma Surgeen2026-07-20T00:00:00.000ZClinical Characteristics and Outcomes of Adult Patients Presenting to the Emergency Department After Hanging: An Eight-Year Retrospective Studyhttps://www.pharmaradar360.com/article/effects-of-practice-testing-with-corrective-feedback-on-long-term-bpsd-knowledge-f0351eefe220bde8Pharma Surgeen2026-07-20T00:00:00.000ZEffects of Practice Testing with Corrective Feedback on Long-Term BPSD Knowledge in Dementia Caregivers: Randomized Controlled Trialhttps://www.pharmaradar360.com/article/social-inequities-in-high-risk-neonatal-care-delivery-clinical-report-445e5bfc2f37a182Pharma Surgeen2026-07-20T00:00:00.000ZSocial Inequities in High-Risk Neonatal Care Delivery: Clinical Reporthttps://www.pharmaradar360.com/article/clinical-legal-education-in-international-environmental-disputes-lessons-from-th-d845e54ad559f760Pharma Surgeen2026-07-20T00:00:00.000ZClinical Legal Education in International Environmental Disputes: Lessons from the Montara Oil Spill Disputehttps://www.pharmaradar360.com/article/comparative-efficacy-of-promising-targets-in-the-treatment-of-metabolic-dysfunct-caf7000126f1a8b8Pharma Surgeen2026-07-20T00:00:00.000ZComparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysishttps://www.pharmaradar360.com/article/propensity-score-matched-external-controls-in-rare-disease-trials-a-promising-to-304a7558599a6773Pharma Surgeen2026-07-20T00:00:00.000ZPropensity Score–Matched External Controls in Rare Disease Trials: A Promising Tool Requiring Rigorous Validationhttps://www.pharmaradar360.com/article/neoadjuvant-sacituzumab-govitecan-in-patients-with-muscle-invasive-bladder-cance-b9c1d0176e76f110Pharma Surgeen2026-07-20T00:00:00.000ZNeoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trialhttps://www.pharmaradar360.com/article/integrative-molecular-analysis-reveals-determinants-of-clinical-outcomes-in-i-tp-9a666ee8e92ed002Pharma Surgeen2026-07-20T00:00:00.000ZIntegrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i> -Mutated Diffuse Large B-Cell Lymphomahttps://www.pharmaradar360.com/article/clinical-memory-functionalisation-and-fragmentation-of-care-in-uk-psychiatry-3d2ffea0d0590ad0Pharma Surgeen2026-07-20T00:00:00.000ZClinical memory, functionalisation and fragmentation of care in UK psychiatryhttps://www.pharmaradar360.com/article/diagnostic-and-clinical-impact-of-point-of-care-ultrasonography-in-internal-medi-e7b6f33867f50136Pharma Surgeen2026-07-20T00:00:00.000ZDiagnostic and clinical impact of point-of-care ultrasonography in internal medicine wards: a systematic review of its role in imaging-guided decision-makinghttps://www.pharmaradar360.com/article/lumefantrine-quantification-on-pre-treated-filter-paper-dried-blood-spots-for-cl-bf894c3a6b580cb1Pharma Surgeen2026-07-20T00:00:00.000ZLumefantrine quantification on pre-treated filter paper dried blood spots for clinical field trialshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-albendazole-versus-praziquantel-in-the-treatment-of-clono-e43d33f6f124fcf5Pharma Surgeen2026-07-20T00:00:00.000ZEfficacy and safety of albendazole versus praziquantel in the treatment of Clonorchis sinensis infection: an infection intensity-stratified, open-label, phase 2, randomized controlled trialhttps://www.pharmaradar360.com/article/effectiveness-of-s-prg-based-varnish-and-bioactive-glass-based-air-polishing-in-c92066bd94951723Pharma Surgeen2026-07-20T00:00:00.000ZEffectiveness of S-PRG–based varnish and bioactive glass–based air polishing in the management of dentin hypersensitivity and their effects on tooth color: a 12-month randomized clinical trialhttps://www.pharmaradar360.com/article/effects-of-resistance-band-shoulder-exercise-on-pain-range-of-motion-and-functio-492d780dcc9eba7bPharma Surgeen2026-07-20T00:00:00.000ZEffects of resistance-band shoulder exercise on pain, range of motion, and functional disability in diabetic adults with adhesive capsulitis: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-brachial-plexus-block-manipulation-versus-stero-130bce84d291b7e3Pharma Surgeen2026-07-20T00:00:00.000ZA randomized controlled trial of brachial plexus block manipulation versus steroid injection in conscious patients for moderate to severe shoulder stiffnesshttps://www.pharmaradar360.com/article/long-term-clinical-outcomes-and-complications-after-open-reduction-and-internal-6d4757ff05dbb25fPharma Surgeen2026-07-20T00:00:00.000ZLong-term clinical outcomes and complications after Open Reduction and Internal Fixation (ORIF) with locking plate for proximal humerus fractures: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/a-novel-homozygous-frameshift-mutation-in-cfap65-is-associated-with-multiple-mor-64fbf1f475d767cdPharma Surgeen2026-07-20T00:00:00.000ZA novel homozygous frameshift mutation in CFAP65 is associated with multiple morphological abnormalities of sperm flagella in a consanguineous Pakistani familyhttps://www.pharmaradar360.com/article/integrated-proteomics-and-machine-learning-for-identifying-candidate-serum-bioma-f56f367ae6b92f78Pharma Surgeen2026-07-20T00:00:00.000ZIntegrated proteomics and machine learning for identifying candidate serum biomarkers in acute myocardial infarction-complicated cardiogenic shock: a prospective exploratory studyhttps://www.pharmaradar360.com/article/sperm-mitochondrial-dna-copy-number-and-nuclear-dna-methylation-across-clinical-d18f99a1b0b0afb6Pharma Surgeen2026-07-20T00:00:00.000ZSperm Mitochondrial DNA Copy Number and Nuclear DNA Methylation Across Clinical and Non‐Clinical Preconception Cohortshttps://www.pharmaradar360.com/article/in-favor-d76f6e3433bb22faPharma Surgeen2026-07-20T00:00:00.000ZIn Favorhttps://www.pharmaradar360.com/article/a-monte-carlo-simulation-tool-to-analyze-breast-cancer-trial-outcomes-applicatio-d1709bb0e502ba8fPharma Surgeen2026-07-20T00:00:00.000ZA Monte Carlo simulation tool to analyze breast cancer trial outcomes: application to FAST-Forward trialhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-a-novel-532-nm-picosecond-nd-yag-laser-for-the-treatment-c18aa9a38b2fe257Pharma Surgeen2026-07-20T00:00:00.000ZEfficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trialhttps://www.pharmaradar360.com/article/the-changing-face-of-uk-academic-drug-screening-in-the-past-decade-c4f3cf6842d0fb96Pharma Surgeen2026-07-20T00:00:00.000ZThe changing face of UK academic drug screening in the past decadehttps://www.pharmaradar360.com/article/comparative-evaluation-of-anti-cancer-activity-of-free-and-nano-encapsulated-gal-b328ec73edd305efPharma Surgeen2026-07-20T00:00:00.000ZComparative evaluation of anti-cancer activity of free and nano-encapsulated gallic acid in PC-3 and HEK-293 cellshttps://www.pharmaradar360.com/article/genomic-insights-and-pathogenic-potential-of-begomovirus-infecting-bitter-gourd-b4d51e30acf35774Pharma Surgeen2026-07-20T00:00:00.000ZGenomic insights and pathogenic potential of begomovirus infecting bitter gourd (Momordica charantia L.) in Tamil nadu, Indiahttps://www.pharmaradar360.com/article/sildenafil-associated-severe-cholestatic-drug-induced-liver-injury-presenting-as-bc95b674f4c8fb91Pharma Surgeen2026-07-20T00:00:00.000ZSildenafil-associated severe cholestatic drug-induced liver injury presenting as persistent jaundice after stone extractionhttps://www.pharmaradar360.com/article/clinical-remission-with-ff-umec-vi-versus-ics-laba-in-uncontrolled-asthma-the-pe-a29ba614d519d472Pharma Surgeen2026-07-20T00:00:00.000ZClinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-usefulness-of-slab-selective-three-dimensional-magnetic-resonance-angio-c0894178ea0b833fPharma Surgeen2026-07-20T00:00:00.000ZClinical usefulness of slab-selective three-dimensional magnetic resonance angiography using radial stack-of-stars acquisition and UTE sampling (STARS UTE-MRA) after treatment of cerebral aneurysms with metallic deviceshttps://www.pharmaradar360.com/article/deciphering-survival-disparities-in-endometrial-cancer-a-focus-on-mismatch-repai-034298080b5f310fPharma Surgeen2026-07-20T00:00:00.000ZDeciphering survival disparities in endometrial cancer: a focus on mismatch repair pathway integrity (systematic review and meta-analysis)https://www.pharmaradar360.com/article/research-evolution-and-clinical-positioning-of-robot-assisted-simple-prostatecto-926a42128cd0704cPharma Surgeen2026-07-20T00:00:00.000ZResearch evolution and clinical positioning of robot-assisted simple prostatectomy for benign prostatic hyperplasia: a bibliometric and visualization analysishttps://www.pharmaradar360.com/article/mapping-the-evolution-of-deep-learning-and-computer-vision-in-robotic-surgery-a-898ea3c81aa196b7Pharma Surgeen2026-07-20T00:00:00.000ZMapping the evolution of deep learning and computer vision in robotic surgery: a bibliometric analysis of surgical video intelligence, instrument perception, and clinical translationhttps://www.pharmaradar360.com/article/dfdba-plus-t-prf-with-and-without-vitamin-d3-gel-in-intrabony-defects-a-randomiz-94b6a4bbaf17b04bPharma Surgeen2026-07-20T00:00:00.000ZDFDBA plus T-PRF with and without vitamin D3 gel in intrabony defects: a randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-medical-mud-pack-therapy-on-inflammatory-gene-expression-and-clinical-47650b73d2ae0513Pharma Surgeen2026-07-20T00:00:00.000ZEffects of medical mud-pack therapy on inflammatory gene expression and clinical outcomes in patients with knee osteoarthritishttps://www.pharmaradar360.com/article/association-between-pupil-size-and-response-to-atropine-therapy-in-the-atropine-5f7c987ebc2a0ac8Pharma Surgeen2026-07-20T00:00:00.000ZAssociation between pupil size and response to atropine therapy in the Atropine Treatment of Myopia study (ATOM2)https://www.pharmaradar360.com/article/effect-of-vicryl-7-0-suturing-versus-diathermy-closure-on-the-ocular-surface-aft-81bf35af238f9a96Pharma Surgeen2026-07-20T00:00:00.000ZEffect of vicryl 7 − 0 suturing versus diathermy closure on the ocular surface after small-gauge vitrectomy: a prospective randomized studyhttps://www.pharmaradar360.com/article/acceleration-of-canine-retraction-with-conventional-versus-modified-piezocision-5b851e5df0784193Pharma Surgeen2026-07-20T00:00:00.000ZAcceleration of canine retraction with conventional versus modified piezocision techniqueshttps://www.pharmaradar360.com/article/serum-methylmalonic-acid-levels-and-epilepsy-prevalence-association-analysis-exp-e80865bd5ca369a3Pharma Surgeen2026-07-20T00:00:00.000ZSerum methylmalonic acid levels and epilepsy prevalence: Association analysis, exploratory mediation, and clinical corroborationhttps://www.pharmaradar360.com/article/from-models-to-meaning-the-integrator-pharmacologist-s-role-in-advancing-health-a8b57ac0015eb1f7Pharma Surgeen2026-07-20T00:00:00.000ZFrom Models to Meaning: The Integrator Pharmacologist's Role in Advancing Health Equity Across the Drug Development Continuumhttps://www.pharmaradar360.com/article/why-korea-why-now-korean-biotech-looks-to-taiwan-as-asia-s-next-partnership-fron-efd4296bf9c89720Pharma Surgeen2026-07-19T23:41:59.000ZWhy Korea, Why Now? Korean Biotech Looks to Taiwan as Asia’s Next Partnership Frontierhttps://www.pharmaradar360.com/article/australia-and-taiwan-build-a-faster-clinical-bridge-for-global-biotech-developme-42cebe2b1d863e81Pharma Surgeen2026-07-19T23:41:59.000ZAustralia and Taiwan Build a Faster Clinical Bridge for Global Biotech Developmenthttps://www.pharmaradar360.com/article/japan-looks-beyond-its-borders-to-build-the-next-generation-of-biotech-innovatio-da1aff47b030a8abPharma Surgeen2026-07-19T23:41:59.000ZJapan Looks Beyond Its Borders to Build the Next Generation of Biotech Innovationhttps://www.pharmaradar360.com/article/india-s-life-sciences-proposition-expands-from-global-scale-to-strategic-innovat-9d626b894db77603Pharma Surgeen2026-07-19T23:41:59.000ZIndia’s Life Sciences Proposition Expands from Global Scale to Strategic Innovationhttps://www.pharmaradar360.com/article/poland-and-taiwan-turn-biotech-dialogue-into-partnership-at-bio-asia-taiwan-2026-b7a7e5b51adbd7a2Pharma Surgeen2026-07-19T23:41:59.000ZPoland and Taiwan Turn Biotech Dialogue into Partnership at BIO Asia–Taiwan 2026https://www.pharmaradar360.com/article/hong-kong-makes-its-case-as-asia-s-biotech-super-connector-capital-regulation-an-6ffb8d0b57d4d9b4Pharma Surgeen2026-07-19T23:41:59.000ZHong Kong Makes Its Case as Asia’s Biotech Super-Connector: Capital, Regulation and Scale Convergehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-ha-tay-pharmaceutical-jsc-hnx-dht-89a64fafb4607a44Pharma Surgeen2026-07-19T23:37:17.000ZEnterprise value to EBIT forward of Ha Tay Pharmaceutical JSC – HNX:DHThttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-zhejiang-haisen-pharmaceutical-co-ltd-cla-50a40b267ffc650ePharma Surgeen2026-07-19T23:33:04.000ZEnterprise value to revenue forward of Zhejiang Haisen Pharmaceutical Co., Ltd. Class A – SZSE:001367https://www.pharmaradar360.com/article/neuronata-r-retains-conditional-approval-in-south-korea-816eb340228baef2Pharma Surgeen2026-07-19T23:27:54.000ZNeuronata-R retains conditional approval in South Koreahttps://www.pharmaradar360.com/article/aimedbio-expands-french-clinical-trial-of-adc-bi-4060107-licensed-to-boehringer-34d65646adadebfbPharma Surgeen2026-07-19T23:11:52.000ZAimedBio expands French clinical trial of ADC ‘BI 4060107’ licensed to Boehringer Ingelheimhttps://www.pharmaradar360.com/article/isomorphic-megadeal-lifts-uk-biotech-funding-to-five-year-high-6a49856b20f936dePharma Surgeen2026-07-19T23:06:09.000ZIsomorphic megadeal lifts UK biotech funding to five-year highhttps://www.pharmaradar360.com/article/neuronata-r-retains-conditional-approval-in-south-korea-7982df6561fd77d9Pharma Surgeen2026-07-19T23:00:00.000ZNeuronata-R retains conditional approval in South Koreahttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-zhejiang-haisen-pharmaceutical-co-ltd-class-a-szse-2ce8117ecd7c8c67Pharma Surgeen2026-07-19T22:23:13.000ZPrice to earnings forward of Zhejiang Haisen Pharmaceutical Co., Ltd. Class A – SZSE:001367https://www.pharmaradar360.com/article/price-to-earnings-forward-of-guizhou-xinbang-pharmaceutical-co-ltd-class-a-szse-cf874761c44aa247Pharma Surgeen2026-07-19T21:54:48.000ZPrice to earnings forward of Guizhou Xinbang Pharmaceutical Co., Ltd. Class A – SZSE:002390https://www.pharmaradar360.com/article/usda-fsis-fda-and-epa-release-mou-clarifying-interagency-cooperation-on-chemical-2c1296565f95d44cPharma Surgeen2026-07-19T21:25:07.000ZUSDA-FSIS, FDA, and EPA Release MOU Clarifying Interagency Cooperation on Chemical Contaminants in Meat, Poultry, and Egg Productshttps://www.pharmaradar360.com/article/veradermics-reports-positive-phase-2-hair-loss-drug-trial-results-112d312a9a114e43Pharma Surgeen2026-07-19T20:51:00.000ZVeradermics Reports Positive Phase 2 Hair Loss Drug Trial Resultshttps://www.pharmaradar360.com/article/price-to-book-forward-of-tian-an-pharmaceutical-co-ltd-otc-tnph-ee72b9e386707e0cPharma Surgeen2026-07-19T19:10:03.000ZPrice to book forward of Tian'an Pharmaceutical Co., Ltd. – OTC:TNPHhttps://www.pharmaradar360.com/article/german-biotech-company-behind-covid-19-vaccine-took-its-first-steps-with-help-fr-b4b77dc18d725a44Pharma Surgeen2026-07-19T19:02:07.000ZGerman biotech company behind COVID-19 vaccine took its first steps with help from the ERDFhttps://www.pharmaradar360.com/article/dimerix-acquires-phase-ii-ready-dmx-652-to-expand-kidney-disease-pipeline-91096a1412a936dfPharma Surgeen2026-07-19T18:31:45.000ZDimerix Acquires Phase II-Ready DMX-652 to Expand Kidney Disease Pipelinehttps://www.pharmaradar360.com/article/latigo-preps-ipo-to-fund-non-opioid-rival-to-vertex-s-journax-8d56612354aa7519Pharma Surgeen2026-07-19T18:07:34.000ZLatigo preps IPO to fund non-opioid rival to Vertex’s Journaxhttps://www.pharmaradar360.com/article/sii-gates-mri-ink-pact-to-manufacture-new-tb-vaccine-candidate-after-successful-ed2faa3c236b2d66Pharma Surgeen2026-07-19T17:50:55.000ZSII & Gates MRI ink pact to manufacture new TB vaccine candidate after successful phase 3 trialshttps://www.pharmaradar360.com/article/merck-pill-becomes-first-oral-option-in-growing-class-of-cholesterol-lowering-dr-84fc63ee067be400Pharma Surgeen2026-07-19T17:17:26.000ZMerck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugshttps://www.pharmaradar360.com/article/world-pharmaceutical-grade-polyethylene-glycol-market-analysis-forecast-size-tre-c3c28dd3de3a487aPharma Surgeen2026-07-19T16:46:14.000ZWorld Pharmaceutical Grade Polyethylene Glycol - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/the-medical-minute-psychedelics-cannabis-glp-1s-and-drug-policy-changes-83fe6ee2988f52cdPharma Surgeen2026-07-19T16:26:04.000ZThe Medical Minute: Psychedelics, Cannabis, GLP-1s and Drug Policy Changeshttps://www.pharmaradar360.com/article/pakistan-china-seal-440m-pharma-deals-to-power-healthcare-biotech-partnership-f90422e712224aaaPharma Surgeen2026-07-19T15:47:56.000ZPakistan, China seal $440m pharma deals to power healthcare, biotech partnershiphttps://www.pharmaradar360.com/article/houston-s-6-5b-glp-1-megaproject-reveals-what-s-next-5c7d2e3bf0f230e9Pharma Surgeen2026-07-19T15:18:31.000ZHouston’s $6.5B GLP-1 megaproject reveals what's nexthttps://www.pharmaradar360.com/article/the-medical-minute-psychedelics-cannabis-glp-1s-and-drug-policy-changes-18cb84abe0a4088ePharma Surgeen2026-07-19T15:02:46.000ZThe Medical Minute: Psychedelics, Cannabis, GLP-1s and Drug Policy Changeshttps://www.pharmaradar360.com/article/the-market-for-psychedelic-drugs-to-treat-mental-health-conditions-gets-a-big-bu-b93429152ca8caf6Pharma Surgeen2026-07-19T14:45:37.000ZThe market for psychedelic drugs to treat mental health conditions gets a big buy signalhttps://www.pharmaradar360.com/article/why-did-servier-pay-a-68-premium-for-day-one-biopharmaceuticals-3134585681070559Pharma Surgeen2026-07-19T14:41:11.000ZWhy Did Servier Pay a 68% Premium for Day One Biopharmaceuticalshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-guizhou-xinbang-pharmaceutical-co-ltd-class-a-szse-002-3700a58a555f75f3Pharma Surgeen2026-07-19T14:29:02.000ZPrice to sales forward of Guizhou Xinbang Pharmaceutical Co., Ltd. Class A – SZSE:002390https://www.pharmaradar360.com/article/should-west-s-10-year-global-daikyo-distribution-pact-reshape-the-glp-1-narrativ-164ad4b933ab6f33Pharma Surgeen2026-07-19T14:24:15.000ZShould West’s 10-Year Global Daikyo Distribution Pact Reshape the GLP-1 Narrative for WST Investors?https://www.pharmaradar360.com/article/the-mresvax-rsv-vaccine-moderna-bets-on-maternal-protection-in-late-stage-testin-db835924ccaf3199Pharma Surgeen2026-07-19T14:20:56.000ZThe mRESVAX RSV vaccine - Moderna bets on maternal protection in late-stage testinghttps://www.pharmaradar360.com/article/did-fda-suspend-mysore-cafe-s-licence-social-media-abuzz-with-claims-what-we-kno-ef53c787c5878d14Pharma Surgeen2026-07-19T14:05:26.000ZDid FDA Suspend Mysore Cafe's Licence? Social Media Abuzz With Claims — What We Knowhttps://www.pharmaradar360.com/article/fda-accepts-bmrn-s-snda-seeking-full-approval-for-voxzogo-b95128be3e81c251Pharma Surgeen2026-07-19T13:24:55.000ZFDA accepts BMRN's sNDA seeking full approval for Voxzogohttps://www.pharmaradar360.com/article/protagonist-therapeutics-ptgx-rises-in-biotech-rally-while-valuation-keeps-the-d-dc17aa3efb04337bPharma Surgeen2026-07-19T12:31:40.000ZProtagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Openhttps://www.pharmaradar360.com/article/javelin-biotech-and-pfizer-announce-landmark-publication-demonstr-28d86ca0d0549e66Pharma Surgeen2026-07-19T12:15:49.000ZJavelin Biotech and Pfizer Announce Landmark Publication Demonstrhttps://www.pharmaradar360.com/article/k-bio-aims-for-30-billion-in-technology-exports-amid-growing-competitiveness-bea9c154ad118355Pharma Surgeen2026-07-19T11:56:39.000ZK-Bio Aims for $30 Billion in Technology Exports Amid Growing Competitivenesshttps://www.pharmaradar360.com/article/ai-in-drug-discovery-from-target-identification-to-clinical-translation-8ddc09a0914c349fPharma Surgeen2026-07-19T11:36:21.000ZAI in drug discovery: From target identification to clinical translationhttps://www.pharmaradar360.com/article/the-bull-case-for-cosmos-pharmaceutical-tse-3349-could-change-following-dividend-623c119a812d6497Pharma Surgeen2026-07-19T11:20:31.000ZThe Bull Case For COSMOS Pharmaceutical (TSE:3349) Could Change Following Dividend Shift And 2027 Guidancehttps://www.pharmaradar360.com/article/rossari-biotech-reports-strong-financial-performance-for-q1-fy27-5f1f3eebd741b500Pharma Surgeen2026-07-19T11:18:12.000ZRossari Biotech reports strong financial performance for Q1 FY27https://www.pharmaradar360.com/article/rossari-biotech-releases-q1-fy27-earnings-presentation-d31a1d99f5d41891Pharma Surgeen2026-07-19T10:58:05.000ZRossari Biotech releases Q1 FY27 earnings presentationhttps://www.pharmaradar360.com/article/rossari-biotech-q1-fy27-revenue-soars-28-to-697-cr-margins-dip-bb21065ba9a5c495Pharma Surgeen2026-07-19T10:51:53.000ZRossari Biotech Q1 FY27 Revenue Soars 28% to ₹697 Cr; Margins Diphttps://www.pharmaradar360.com/article/seb-asset-management-ab-invests-59-55-million-in-teva-pharmaceutical-industries-94094d44671a4230Pharma Surgeen2026-07-19T10:42:18.000ZSEB Asset Management AB Invests $59.55 Million in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ocugen-targets-259-million-in-mena-licensing-deal-for-ocu400-1768dd0780fcff2ePharma Surgeen2026-07-19T10:41:15.000ZOcugen Targets $259 Million in MENA Licensing Deal for OCU400https://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-07-19T10:40:50.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/k-bio-aims-for-30-billion-in-technology-exports-amid-growing-competitiveness-575a3d1447930dccPharma Surgeen2026-07-19T10:04:00.000ZK-Bio Aims for $30 Billion in Technology Exports Amid Growing Competitivenesshttps://www.pharmaradar360.com/article/afghan-uzbek-officials-discuss-expanding-cooperation-in-pharmaceutical-sector-2b190d9acaf38471Pharma Surgeen2026-07-19T09:58:05.000ZAfghan, Uzbek officials discuss expanding cooperation in pharmaceutical sectorhttps://www.pharmaradar360.com/article/insmed-reports-positive-12-month-tpip-pah-study-data-a132b9e7d0a81af4Pharma Surgeen2026-07-19T09:35:41.000ZInsmed Reports Positive 12-Month TPIP PAH Study Datahttps://www.pharmaradar360.com/article/moderna-doses-first-patient-in-mrna-4200-cancer-trial-1584db9dd605e884Pharma Surgeen2026-07-19T09:33:57.000ZModerna Doses First Patient in mRNA-4200 Cancer Trialhttps://www.pharmaradar360.com/article/pakistan-assures-chinese-investors-of-full-backing-for-health-care-pharmaceutica-c1ccac91f5d5a010Pharma Surgeen2026-07-19T09:21:23.000ZPakistan assures Chinese investors of full backing for health care, pharmaceutical investmentshttps://www.pharmaradar360.com/article/104-katsis-1-randomized-phase-3-trial-evaluating-kat6-inhibitor-pf-07248144-prif-539f635c496c4225Pharma Surgeen2026-07-19T09:17:47.000Z104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapyhttps://www.pharmaradar360.com/article/zhuhai-trinomab-pharmaceutical-co-ltd-2e647125db9c5985Pharma Surgeen2026-07-19T09:12:24.000ZZhuhai Trinomab Pharmaceutical Co Ltdhttps://www.pharmaradar360.com/article/allspring-global-investments-holdings-llc-sells-159-581-shares-of-teva-pharmaceu-65fcd6c88fd03333Pharma Surgeen2026-07-19T08:11:01.000ZAllspring Global Investments Holdings LLC Sells 159,581 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/financial-authorities-are-planning-to-present-principles-that-should-be-followed-75bcd09eff687aabPharma Surgeen2026-07-19T08:09:00.000ZFinancial authorities are planning to present principles that should be followed in the media promot..https://www.pharmaradar360.com/article/evonik-opens-new-active-pharmaceutical-ingredient-manufacturing-facility-in-indi-6ec27a61993cc394Pharma Surgeen2026-07-19T08:08:07.000ZEvonik Opens New Active Pharmaceutical Ingredient Manufacturing Facility In Indianahttps://www.pharmaradar360.com/article/kenya-woos-diplomats-to-back-pharmaceutical-manufacturing-drive-c2c2a135d6c5e699Pharma Surgeen2026-07-19T08:03:14.000ZKenya woos diplomats to back pharmaceutical manufacturing drivehttps://www.pharmaradar360.com/article/what-caused-uniqure-s-dramatic-stock-plunge-ae416357f9ef1711Pharma Surgeen2026-07-19T07:35:38.000ZWhat Caused uniQure's Dramatic Stock Plungehttps://www.pharmaradar360.com/article/pune-registers-highest-food-safety-complaints-since-fda-portal-launch-b36ae63a24133479Pharma Surgeen2026-07-19T07:34:26.000ZPune Registers Highest Food Safety Complaints Since FDA Portal Launchhttps://www.pharmaradar360.com/article/moph-holds-meeting-in-farah-on-enforcement-of-anti-drug-smuggling-law-and-new-ph-53a7ecf232290123Pharma Surgeen2026-07-19T07:29:53.000ZMoPH Holds Meeting in Farah on Enforcement of Anti-Drug Smuggling Law and New Pharmaceutical Regulationshttps://www.pharmaradar360.com/article/west-pharmaceutical-stock-trades-steady-as-recent-earnings-and-innovation-invest-cbba063a9c1089f0Pharma Surgeen2026-07-19T07:29:50.000ZWest Pharmaceutical stock trades steady as recent earnings and innovation investments shape outlookhttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524Pharma Surgeen2026-07-19T07:29:08.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/india-eyes-2-6-tn-bioeconomy-by-2047-charts-roadmap-to-global-biotech-leadership-12f7aabfc40a3033Pharma Surgeen2026-07-19T07:19:57.000ZIndia Eyes $2.6 Tn Bioeconomy By 2047, Charts Roadmap To Global Biotech Leadershiphttps://www.pharmaradar360.com/article/takeda-s-zasocitinib-delivers-broad-skin-clearance-in-phase-3-psoriasis-trials-f9598e0c11418252Pharma Surgeen2026-07-19T07:03:53.000ZTakeda’s zasocitinib delivers broad skin clearance in Phase 3 psoriasis trialshttps://www.pharmaradar360.com/article/grifols-advances-immunoglobulin-pipeline-with-two-new-phase-3-trials-c632146c2c41ca8bPharma Surgeen2026-07-19T07:03:53.000ZGrifols advances immunoglobulin pipeline with two new Phase 3 trialshttps://www.pharmaradar360.com/article/how-modern-biotech-drives-nigeria-s-agricultural-rebirth-c228a32063cb63d3Pharma Surgeen2026-07-19T06:58:11.000ZHow modern biotech drives Nigeria’s agricultural rebirthhttps://www.pharmaradar360.com/article/pune-tops-maharashtra-in-complaints-over-unhygienic-food-d3803e4ca107e223Pharma Surgeen2026-07-19T06:48:41.000ZPune tops Maharashtra in complaints over unhygienic foodhttps://www.pharmaradar360.com/article/the-blood-brain-barrier-has-been-breached-is-clinical-trial-science-ready-10e818a8e8587a8fPharma Surgeen2026-07-19T06:45:18.000ZThe Blood-Brain Barrier Has Been Breached. Is Clinical Trial Science Ready?https://www.pharmaradar360.com/article/pune-records-highest-unhygienic-food-complaints-across-maharashtra-134b8640cd2e9c31Pharma Surgeen2026-07-19T06:43:36.000ZPune records highest unhygienic food complaints across Maharashtrahttps://www.pharmaradar360.com/article/4d-molecular-therapeutics-nasdaq-fdmt-reports-two-year-gene-therapy-data-showing-6aead7d7dd563457Pharma Surgeen2026-07-19T06:31:25.000Z4D Molecular Therapeutics (NASDAQ: FDMT) Reports Two-Year Gene Therapy Data Showing 87% Treatment Burden Reduction In Wet AMD Patientshttps://www.pharmaradar360.com/article/acetyl-chloride-market-growth-outlook-to-2035-pharmaceutical-and-agrochemical-dr-d46bbba1998563e1Pharma Surgeen2026-07-19T06:21:13.000ZAcetyl Chloride Market Growth Outlook to 2035: Pharmaceutical and Agrochemical Drivers - News and Statisticshttps://www.pharmaradar360.com/article/fda-approves-first-oral-pcsk9-inhibitor-but-will-lower-ldl-translate-into-fewer-b8f6e20eda498f22Pharma Surgeen2026-07-19T06:14:33.000ZFDA Approves First Oral PCSK9 Inhibitor—but Will Lower LDL Translate Into Fewer Heart Attacks?https://www.pharmaradar360.com/article/price-to-sales-forward-of-tian-an-pharmaceutical-co-ltd-otc-tnph-5077ee050632dc2ePharma Surgeen2026-07-19T05:42:08.000ZPrice to sales forward of Tian'an Pharmaceutical Co., Ltd. – OTC:TNPHhttps://www.pharmaradar360.com/article/pharma-industry-s-next-big-leap-0d66ac06f631925aPharma Surgeen2026-07-19T04:59:33.000ZPharma industry’s next big leaphttps://www.pharmaradar360.com/article/grunenthal-joins-munich-genetic-medicine-cluster-to-advance-rna-therapies-427058e86267c47ePharma Surgeen2026-07-19T04:42:37.000ZGrunenthal joins Munich genetic medicine cluster to advance RNA therapieshttps://www.pharmaradar360.com/article/kobo-biotech-these-9-penny-stocks-rallied-up-to-360-in-6-months-4-turned-multiba-69d8d132cbcff920Pharma Surgeen2026-07-19T04:37:54.000ZKobo Biotech - These 9 penny stocks rallied up to 360% in 6 months; 4 turned multibaggershttps://www.pharmaradar360.com/article/fda-crackdown-in-maharashtra-pune-records-highest-number-of-unhygienic-food-comp-0d1e56f3050caa34Pharma Surgeen2026-07-19T04:18:42.000ZFDA crackdown in Maharashtra: Pune records highest number of unhygienic food complaintshttps://www.pharmaradar360.com/article/pune-tops-maharashtra-in-complaints-over-unhygienic-food-says-fda-b3a2581a2c586266Pharma Surgeen2026-07-19T03:02:26.000ZPune tops Maharashtra in complaints over unhygienic food, says FDAhttps://www.pharmaradar360.com/article/pune-reports-highest-unhygienic-food-complaints-in-maharashtra-22f77878d2ad344bPharma Surgeen2026-07-19T02:54:06.000ZPune Reports Highest Unhygienic Food Complaints In Maharashtrahttps://www.pharmaradar360.com/article/world-cbd-extraction-equipment-market-analysis-forecast-size-trends-and-insights-12d7c45f7b0c6734Pharma Surgeen2026-07-19T02:31:12.000ZWorld Cbd Extraction Equipment - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/pakistan-china-pharma-conference-ends-with-850m-agreements-ff7f1efd8c8b7fdcPharma Surgeen2026-07-19T02:01:37.000ZPakistan-China pharma conference ends with $850m agreementshttps://www.pharmaradar360.com/article/kolon-tissuegene-plunges-20-ahead-of-tg-c-phase-3-results-4253542bd73b978fPharma Surgeen2026-07-19T02:01:05.000ZKolon TissueGene Plunges 20% Ahead of TG-C Phase 3 Resultshttps://www.pharmaradar360.com/article/rajnath-singh-pitches-india-as-global-healing-and-wellness-capital-2600cf7931beadabPharma Surgeen2026-07-19T01:44:00.000ZRajnath Singh pitches India as global healing and wellness capitalhttps://www.pharmaradar360.com/article/ish-nokady-provedet-provedet-prezentatsionnyy-den-pharmaceutical-technical-unive-b7dcea9348e6556aPharma Surgeen2026-07-19T01:14:40.000ZIsh nokady provedet provedet prezentatsionnyy den pharmaceutical technical universityhttps://www.pharmaradar360.com/article/the-high-stakes-reality-of-the-weight-loss-drug-boom-0df46c7eeed6d971Pharma Surgeen2026-07-19T00:58:25.000ZThe High-Stakes Reality of the Weight-Loss Drug Boomhttps://www.pharmaradar360.com/article/eli-lilly-to-buy-psychedelics-maker-ataibeckley-for-2-8-billion-as-experimental-1c0aed4882ad2971Pharma Surgeen2026-07-19T00:53:23.000ZEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain tractionhttps://www.pharmaradar360.com/article/eicosapentaenoic-acid-market-growth-forecast-to-2035-pharmaceutical-demand-and-a-458d5c16b661c654Pharma Surgeen2026-07-19T00:36:14.000ZEicosapentaenoic Acid Market Growth Forecast to 2035: Pharmaceutical Demand and Algal Fermentation Drive Expansion - News and Statisticshttps://www.pharmaradar360.com/article/zentalis-to-present-azenosertib-data-at-esmo-2026-d2134391da21ad8cPharma Surgeen2026-07-19T00:11:45.000ZZentalis to Present Azenosertib Data at ESMO 2026https://www.pharmaradar360.com/article/assessment-of-knowledge-and-clinical-practice-patterns-in-restorative-material-s-d373b6067a48fb32Pharma Surgeen2026-07-19T00:00:00.000ZAssessment of Knowledge and Clinical Practice Patterns in Restorative Material Selection for Anterior Teeth Among Dental Practitionershttps://www.pharmaradar360.com/article/evaluating-the-impact-of-participating-in-knights-keeping-neighbors-in-good-heal-ab2b9bbedd9e18e2Pharma Surgeen2026-07-19T00:00:00.000ZEvaluating the Impact of Participating in KNIGHTS (Keeping Neighbors In Good Health Through Service) Clinic on Clinical Performance and Skills Developmenthttps://www.pharmaradar360.com/article/inteligencia-artificial-na-medicina-aplicacoes-clinicas-beneficios-limitacoes-e-7821d744de6fe80dPharma Surgeen2026-07-19T00:00:00.000ZInteligência artificial na medicina: aplicações clínicas, benefícios, limitações e desafios éticoshttps://www.pharmaradar360.com/article/aprendizaje-espaciado-y-neuroplasticidad-en-la-educacion-superior-en-ciencias-de-be5c249319371a0dPharma Surgeen2026-07-19T00:00:00.000ZAprendizaje espaciado y neuroplasticidad en la educación superior en ciencias de la salud: estrategias para fortalecer competencias clínicashttps://www.pharmaradar360.com/article/divergent-lymphocyte-associations-with-depression-severity-and-case-status-in-fi-26006b0c6cb9c9a0Pharma Surgeen2026-07-19T00:00:00.000ZDivergent lymphocyte associations with depression severity and case status in first-episode, drug-naive adolescents: A multicenter studyhttps://www.pharmaradar360.com/article/congqi-shoushen-tuina-method-for-generalized-anxiety-disorder-clinical-outcomes-72ea36e22d7ade73Pharma Surgeen2026-07-19T00:00:00.000ZCongqi Shoushen Tuina Method for generalized anxiety disorder: Clinical outcomes and serum metabolomic profileshttps://www.pharmaradar360.com/article/letter-to-the-editor-temporal-dynamics-of-anxiety-and-depression-from-pregnancy-c77f85f7ecd05b63Pharma Surgeen2026-07-19T00:00:00.000ZLetter to the Editor: Temporal dynamics of anxiety and depression from pregnancy to postpartum: Insights, limitations, and clinical implicationshttps://www.pharmaradar360.com/article/clinical-guidelines-for-adolescent-depression-an-integrated-traditional-chinese-b278ffcd66b13bb8Pharma Surgeen2026-07-19T00:00:00.000ZClinical guidelines for adolescent depression: An integrated traditional Chinese and Western medicine approachhttps://www.pharmaradar360.com/article/clinical-mechanisms-of-continuous-stellate-ganglion-block-in-improving-postopera-e7f254c4e38b7353Pharma Surgeen2026-07-19T00:00:00.000ZClinical mechanisms of continuous stellate ganglion block in improving postoperative anxiety and depression after thoracoscopic lung cancer surgeryhttps://www.pharmaradar360.com/article/clinical-efficacy-of-sihai-shuyu-pill-euthyrox-for-thyroid-nodules-and-real-worl-1c1cb6bfdde569fePharma Surgeen2026-07-19T00:00:00.000ZClinical efficacy of Sihai Shuyu Pill-Euthyrox for thyroid nodules and real-world research on patients’ anxiety/depressionhttps://www.pharmaradar360.com/article/monitoring-the-depth-of-neuromuscular-blockade-in-the-intensive-care-unit-17ca05da298ade82Pharma Surgeen2026-07-19T00:00:00.000ZMonitoring the depth of neuromuscular blockade in the intensive care unithttps://www.pharmaradar360.com/article/an-assessment-of-the-impact-of-training-and-development-on-employee-performance-d46307bca982de31Pharma Surgeen2026-07-19T00:00:00.000ZAn Assessment of the Impact of Training and Development on Employee Performance: Evidence from Afghanistan Food and Drug Authority (AFDA)https://www.pharmaradar360.com/article/projected-impact-of-international-hiv-funding-withdrawal-on-hiv-transmission-car-f381281eb7d52a39Pharma Surgeen2026-07-19T00:00:00.000ZProjected Impact of International HIV Funding Withdrawal on HIV Transmission, Care Continuum Disruption, and AIDS-Related Mortality in Nigeria: A Dynamic Mathematical Modelling Studyhttps://www.pharmaradar360.com/article/faers-based-pharmacovigilance-study-of-sevoflurane-associated-adverse-events-a-2-13aa87b7a0f4e9d7Pharma Surgeen2026-07-19T00:00:00.000ZFAERS-based pharmacovigilance study of sevoflurane-associated adverse events: A 20-year comprehensive analysishttps://www.pharmaradar360.com/article/impact-of-integrating-objectives-and-key-results-into-an-antimicrobial-stewardsh-b85131b5fbabc172Pharma Surgeen2026-07-19T00:00:00.000ZImpact of integrating objectives and key results into an antimicrobial stewardship program: A retrospective analysishttps://www.pharmaradar360.com/article/intra-atrial-conduction-time-physiological-basis-pathophysiological-mechanisms-a-82b89de58f94b2c6Pharma Surgeen2026-07-19T00:00:00.000ZIntra-Atrial Conduction Time: Physiological Basis, Pathophysiological Mechanisms, and Clinical Implicationshttps://www.pharmaradar360.com/article/the-role-of-complementary-and-integrative-medicine-on-assisted-reproductive-tech-2a49d57100e5846dPharma Surgeen2026-07-19T00:00:00.000ZThe Role of Complementary and Integrative Medicine on Assisted Reproductive Technologies Outcomes: A Comprehensive Review of Preclinical and Clinical Evidencehttps://www.pharmaradar360.com/article/herbal-medicine-in-head-and-neck-cancer-a-review-of-randomized-controlled-trial-fd057987b58183c6Pharma Surgeen2026-07-19T00:00:00.000ZHerbal Medicine in Head and Neck Cancer: A Review of Randomized Controlled Trialhttps://www.pharmaradar360.com/article/exploring-the-potential-of-nutraceuticals-in-diabetic-retinopathy-evidence-based-6ac5bed84aac8391Pharma Surgeen2026-07-19T00:00:00.000ZExploring the Potential of Nutraceuticals in Diabetic Retinopathy: Evidence-Based Mechanisms and Clinical Insightshttps://www.pharmaradar360.com/article/rare-coexistence-of-isolated-celiac-artery-dissection-and-superior-mesenteric-ar-d0fa38fc91b7b300Pharma Surgeen2026-07-19T00:00:00.000ZRare coexistence of isolated celiac artery dissection and superior mesenteric artery dissection: diagnosis, treatment, follow-up outcomes of a single patient and clinical implicationshttps://www.pharmaradar360.com/article/prevalence-of-depressive-and-anxiety-symptoms-and-their-sociodemographic-correla-e6cd2fc97f093db5Pharma Surgeen2026-07-19T00:00:00.000ZPrevalence of depressive and anxiety symptoms and their sociodemographic correlates among adult clinical population in Pakistanhttps://www.pharmaradar360.com/article/liposomal-nanocarriers-in-retinoblastoma-from-molecular-design-to-clinical-trans-d4e2e78a6fa39e79Pharma Surgeen2026-07-19T00:00:00.000ZLiposomal nanocarriers in retinoblastoma: from molecular design to clinical translationhttps://www.pharmaradar360.com/article/exploring-pomegranate-peel-extract-as-a-green-synthesizer-for-berberine-chloride-36a584c4affe4ffaPharma Surgeen2026-07-19T00:00:00.000ZExploring Pomegranate Peel Extract as a Green Synthesizer for Berberine Chloride–Loaded Zinc Oxide Nanoparticles: A Novel Approach for Enhanced Antibacterial Efficacyhttps://www.pharmaradar360.com/article/bl-918-as-a-novel-neuroprotective-agent-targeting-smp30-in-parkinson-s-disease-a-f47c8bc164fd6cd4Pharma Surgeen2026-07-19T00:00:00.000ZBL-918 as a Novel Neuroprotective Agent Targeting SMP30 in Parkinson’s Disease: A Therapeutic Evaluationhttps://www.pharmaradar360.com/article/pharmacological-management-of-dyslipidemia-in-obese-and-elderly-patients-challen-528112959ef80160Pharma Surgeen2026-07-19T00:00:00.000ZPharmacological Management of Dyslipidemia in Obese and Elderly Patients: Challenges, Current Therapies, and Emerging Treatmentshttps://www.pharmaradar360.com/article/thai-traditional-polyherbal-infused-oil-t-yasp-accelerates-diabetic-wound-healin-a57a04c1c49f6460Pharma Surgeen2026-07-19T00:00:00.000ZThai Traditional Polyherbal Infused Oil (T-YaSP) Accelerates Diabetic Wound Healing by Modulating Inflammation and Angiogenesis